Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era
Copyright © 2024. Published by Elsevier Ltd..
INTRODUCTION: Whether pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab 150mg/150 mg (T/C) in individuals with hematological diseases (HD) may lead to a reduced risk of Breakthrough SARS CoV2 infection/hospitalization or death in the Omicron era remains to be established.
METHODS: Observational study including participants with HD who received PrEP. breakthrough infections were defined as a SARS-CoV-2 positivity by RT-PCR. The incidence of breakthrough infections (95%CI) and of breakthrough infections /hospitalization/death was calculated using the Kaplan-Meier method and as the number of breakthrough infections per 100-PYFU according to the circulating variant (VoC). A Poisson regression model was used to evaluate the association between the rate of incidence and circulating VoCs after controlling for demographics and clinical factors.
RESULTS: We included 550 HD patients: 71% initiated T/C PrEP when BA.5 was the most prevalent, followed by XBB/EG, BA.2 and BA.1 (19%, 7% and 3%, respectively). Overall, the 1-year incidence estimate of breakthrough infections/hospitalization/death was 24% (18.7-29.4%). A greater risk of incident infections was observed when BA.5 and XBB/EG sub-lineages circulated [aRR 5.05 (2.17, 11.77); p<.001 and 3.82 (1.50, 9.72); p=0.005, compared to BA.1, respectively].
CONCLUSIONS: The one-year incidence of SARS-CoV-2 breakthrough infections/hospitalization/death was 24% which is in line with what observed in other similar studies. The risk appeared to be higher when more recent Omicron sub-lineages were circulating suggesting a reduction of in vitro neutralization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - (2024) vom: 11. Apr., Seite 107042 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vergori, Alessandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID19 |
|---|
| Anmerkungen: |
Date Revised 13.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ijid.2024.107042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371035406 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371035406 | ||
| 003 | DE-627 | ||
| 005 | 20240415232517.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2024.107042 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1375.xml |
| 035 | |a (DE-627)NLM371035406 | ||
| 035 | |a (NLM)38614231 | ||
| 035 | |a (PII)S1201-9712(24)00113-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vergori, Alessandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier Ltd. | ||
| 520 | |a INTRODUCTION: Whether pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab 150mg/150 mg (T/C) in individuals with hematological diseases (HD) may lead to a reduced risk of Breakthrough SARS CoV2 infection/hospitalization or death in the Omicron era remains to be established | ||
| 520 | |a METHODS: Observational study including participants with HD who received PrEP. breakthrough infections were defined as a SARS-CoV-2 positivity by RT-PCR. The incidence of breakthrough infections (95%CI) and of breakthrough infections /hospitalization/death was calculated using the Kaplan-Meier method and as the number of breakthrough infections per 100-PYFU according to the circulating variant (VoC). A Poisson regression model was used to evaluate the association between the rate of incidence and circulating VoCs after controlling for demographics and clinical factors | ||
| 520 | |a RESULTS: We included 550 HD patients: 71% initiated T/C PrEP when BA.5 was the most prevalent, followed by XBB/EG, BA.2 and BA.1 (19%, 7% and 3%, respectively). Overall, the 1-year incidence estimate of breakthrough infections/hospitalization/death was 24% (18.7-29.4%). A greater risk of incident infections was observed when BA.5 and XBB/EG sub-lineages circulated [aRR 5.05 (2.17, 11.77); p<.001 and 3.82 (1.50, 9.72); p=0.005, compared to BA.1, respectively] | ||
| 520 | |a CONCLUSIONS: The one-year incidence of SARS-CoV-2 breakthrough infections/hospitalization/death was 24% which is in line with what observed in other similar studies. The risk appeared to be higher when more recent Omicron sub-lineages were circulating suggesting a reduction of in vitro neutralization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID19 | |
| 650 | 4 | |a Hematological disease | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a pre-exposure prophylaxis | |
| 650 | 4 | |a tixagevimab/cilgavimab | |
| 700 | 1 | |a Lepri, Alessandro Cozzi |e verfasserin |4 aut | |
| 700 | 1 | |a Chiuchiarelli, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzotta, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Metafuni, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Matusali, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Siciliano, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Paulicelli, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Alma, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Siniscalchi, Agostina |e verfasserin |4 aut | |
| 700 | 1 | |a Sica, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Abruzzese, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Fantoni, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Antinori, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cingolani, Antonella |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g (2024) vom: 11. Apr., Seite 107042 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:04 |g pages:107042 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2024.107042 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 04 |h 107042 | ||